MethylDetect’s assay targetting MLH1 gene is now a part of the NICE-mandated Lynch Syndrome pre-screen test.

The results showing the performance of our MLH1 methylation testing assays, performed in collaboration with Sarah Cannon Molecular Diagnostics, https://sarahcannon-md.co.uk , were presented at the National Cancer Research Institute conference 2018.

see:

MLH1 Promoter Hypermethylation: Development and Preliminary Validation of a Methylation-Specific High Resolution Melt Curve Analysis (MS-HRM) Assay for use in a Lynch Syndrome Pre-Screen Pathway

The test was designed for use in accordance with the latest NICE and ACGS guidelines relating to Lynch Syndrome pre-screening, are now available upon demand.